Recent advances in the haploidentical transplant (haplo-HSCT) platforms, particularly the development of in vivo and ex vivo T cell depletion, and the application of post-transplantation cyclophosphamide (PTCy) have drastically improved outcomes [33–35]. Such strategies have resulted in equivalent if not superior outcomes, with OS and EFS values up to 94% of those using matched related and unrelated donors [36, 37].